Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,198,612 papers from all fields of science
Search
Sign In
Create Free Account
ridaforolimus
Known as:
Deforolimus
, Rapamycin, 42-(dimethylphosphinate)
A small molecule and non-prodrug analogue of the lipophilic macrolide antibiotic rapamycin with potential antitumor activity. Ridaforolimus binds to…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
7 relations
Narrower (2)
AP-23573
MK 8669
FRAP1 protein, human
NCIt Antineoplastic Agent Terminology
Signal Transduction Inhibition
analogs & derivatives
Broader (1)
Sirolimus
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Editorial Osteosarcoma : Lessons Learned and Future Avenues
A. Puri
,
N. Jaffe
,
H. Gelderblom
2015
Corpus ID: 265722131
2013
2013
Abstract P2-16-04: A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer
J. Baselga
,
S. Morales
,
+16 authors
H. Rugo
2013
Corpus ID: 57608879
Background: Preclinical studies indicate that the dual inhibition of IGFR and mTOR may be additive or synergistic and abrogates…
Expand
2013
2013
Withdrawal Assessment report for Jenzyl, INN: RIDAFOROLIMUS
2013
Corpus ID: 34219480
This withdrawal Assessment Report is based on the latest assessment report adopted by the CHMP with all information of a…
Expand
2013
2013
Cancer Therapy : Clinical A Multicenter , First-in-Pediatrics , Phase 1 , Pharmacokinetic and Pharmacodynamic Study of Ridaforolimus in Patients with Refractory Solid Tumors
L. Gore
,
T. Trippett
,
+10 authors
M. Nieder
2013
Corpus ID: 33572014
Purpose: Ridaforolimus (MK-8669, AP23573) is a potent and selective mammalian target of rapamycin (mTOR) inhibitor. Preclinically…
Expand
2011
2011
OT3-01-16: A Phase 2 Study of Ridaforolimus (RIDA) and Dalotuzumab (DALO) in Estrogen Receptor Positive (ER+) Breast Cancer.
B. Lu
,
J. Blum
,
+7 authors
J. Baselga
2011
Corpus ID: 71870057
Background: Activation of the PI3K/AKT/mTOR pathway is common in breast cancer. Preclinical studies indicate that the dual…
Expand
2011
2011
Abstract 3513: MK-2206 combined with ridaforolimus or topoisomerase inhibitors synergistically impede the growth of sarcoma cells
C. Cubitt
,
Jillaina L. Menth
,
Jana L. Dawson
,
D. Reed
,
D. Sullivan
2011
Corpus ID: 75742157
The number of effective drugs available for the treatment of soft tissue and bone sarcomas is limited to a small group of…
Expand
2010
2010
A multicenter, first-in-pediatrics phase I study of ridaforolimus (AP23573, MK-8669) in patients (pts) with refractory solid tumors.
L. Gore
,
T. Trippett
,
+7 authors
M. Nieder
2010
Corpus ID: 74695778
9531 Background: The mTOR inhibitor ridaforolimus (R) has shown antitumor activity in adults with sarcomas and other malignancies…
Expand
Review
2009
Review
2009
Drug Combinations as a Therapeutic Approach for mTORC1 Inhibitors in Human Cancer
M. Breuleux
,
H. Lane
2009
Corpus ID: 87444524
A central sensor of the availability of growth factors, nutrients, and energy sources, the mammalian target of rapamycin complex…
Expand
2008
2008
Gateways to clinical trials. July-August 2008.
A. Tomillero
,
M. A. Moral
Methods and Findings in Experimental and Clinical…
2008
Corpus ID: 23111308
(-)-Epigallocatechin gallate, 501516, 89-12; Abatacept, Adalimumab, Adefovir dipivoxil, AG-701, Agatolimod sodium, Alefacept…
Expand
2008
2008
Gateways to clinical trials.
A. Tomillero
,
M. A. Moral
Methods and Findings in Experimental and Clinical…
2008
Corpus ID: 38287257
(-)-Epigallocatechin gallate, (-)-Gossypol; Ad.hIFN-beta, AF-37702, Agatolimod sodium, Agomelatine, Alvocidib hydrochloride, ARC…
Expand